Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 4, 2009 - Issue 8
Submit an article Journal homepage
218
Views
24
CrossRef citations to date
0
Altmetric
Reviews

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity

Gianluca Nucci Clinical Pharmacology, Pfizer Global Research and Development, 50 Pequot Avenue, CT 06320, New London, USA
,
Roberto Gomeni Pharmacometrics and Clinical Pharmacology-Modeling & Simulation, GlaxoSmithKline, Via Fleming 4, 37135, Verona, Italy
&
Italo Poggesi Clinical Pharmacology-Modeling & Simulation, GlaxoSmithKline, Via Fleming 4, Verona, 37135, Italy +39 0458219803; +39 0458218191; [email protected]
Pages 837-856 | Published online: 24 Jun 2009

Bibliography

  • Gomeni R, Bani M, D'Angeli C, et al. Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. Eur J Pharm Sci 2001;13(3):261-70
  • Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res 1992;9(6):826-33
  • Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61(3):275-91
  • Sheiner LB, Steimer J-L. Pharmacokinetic/pharmacodynamic modeling in drug development. Ann Rev Pharmacol Toxicol 2000;40(1):67-95
  • Lesko LJ, Rowland M, Peck CC, et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 2000;10:iv-xiv
  • Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of Clinical Trials. Ann Rev Pharmacol Toxicol 2000;40(1):209-34
  • Zhang L, Sinha V, Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006;33(3):369-93
  • Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007;82(1):21-32
  • Gobburu JVS, Lesko LJ. Quantitative Disease, Drug, and Trial Models. Ann Rev Pharmacol Toxicol 2009;49(1):291-301
  • Available from: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html Critical Path initiative. [Accessed 11 May 2009]
  • Available from: http://www.emea.europa.eu/pdfs/general/direct/directory/3416303enF.pdf Paper “The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future”. [Accessed 11 May 2009]
  • Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68(6):677-87
  • Chabaud S, Girard P, Nony P, Boissel J-P. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokin Pharmacodyn 2002;29(4):339-63
  • Frey N, Laveille C, Paraire M, et al. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 2002;55(2):147-57
  • Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005;7(3):E513-22
  • Kowalski KG, Olson S, Remmers AE, Hutmacher MM. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin Pharmacol Ther 2008;83(6):857-66
  • Barrett JS, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov 2007;2(2):185-209
  • Schmidt S, Schuck E, Kumar V, et al. Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents–minimum inhibitory concentration versus time-kill curves. Expert Opin Drug Discov 2007;2(6):849-60
  • Ette EEI, Williams PJ, editors, Pharmacometrics. The science of quantitative pharmacology. 2007, John Wiley & Sons
  • Cutting J. Descriptive psychopathology. In: Hirsch SR, Weinberger DR, editors, Schizophrenia, Second Edition. Blackwell Science Ltd; 2003. p. 15-24
  • Bhugra D. The global prevalence of schizophrenia. PloS Med 2005;2(5):e151 doi:10.1371/journal.pmed.0020151
  • Castle D, Wesseley S, Der G, Murray RM. The incidence of operationally defined schizophrenia in Camberwell 1965–84. Br J Psychiatry 1991;159(6):790-4
  • Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Ann Rev Med 2007;58(1):49-61
  • Norman RMG, Malla AK, Cortese L, Diaz F. study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Res 1996;19(1):73-85
  • Diagnostic and statistical manual of mental disorders, 4th edition. Washington, American Psychiatric Association (APA), 1994
  • Pierre JM. Deconstructing schizophrenia for DSM-V: challenges for clinical and research agendas. Clin Schizophr Relat Psychoses 2008;2(2):166-74
  • Van den Oord EJ, Rujescu D, Robles JR, et al. Factor structure and external validity of the PANSS revisited. Schizophr Res 2006;82(2-3):213-23
  • Wadenberg M-LG, Kapur S, Soliman A, et al. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behaviour in rats. Psychopharmacol 2000;150(4):422-9
  • Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003;305(2):625-31
  • Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull Advance access published Aug 2008, 22; doi:10.1093/schbul/sbn110
  • Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008;34(2):286-91
  • Lieberman JA, Stroup S, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
  • Gudiksen M, Fleming E, Furstenthal L, Ma P. What drives success for specialty pharmaceuticals? Nat Rev Drug Discov 2008;7(7):563-7
  • Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261(5562): 717-19
  • Talbot PS, Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 2002;12(6):503-11
  • Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360-9
  • Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 2008;22(8):882-94
  • Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251(1):238-46
  • Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry 2002;181(4):271-5
  • Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001;179(6):503-8
  • Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokinetic–pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 2008;584(2-3):318-27
  • Parker TJ, Della Pasqua OE, Loizillon E, et al. Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats. British J Pharmacol 2001;132(1):151-8
  • Deutsch SI, Rosse RB, Billingslea EN, et al. Topiramate antagonizes MK-801 in animal models of schizophrenia. Eur J Pharmacol 2002;449(1-2):121-5
  • Nordquist RE, Risterucci C, Moreau JL, et al. Effect of aripiprazole/OCP-14597 on motor activity, pharmacology models of psychosis, and brain activity in rats. Neuropharmacol 2008;54(2):405-18
  • Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptor: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacol 2006;31(9):1854-63
  • Wong DF, Tauscher J, Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacol Rev 2009;34:187-203
  • Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130(Pt 10):2616-35
  • McGuire PK, Matsumoto K. Functional neuroimaging in mental disorders. World Psychiatry 2004;3(1):6-11
  • Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study in schizophrenic patients. Biol Psychiatry 1993;33(4):227-35
  • Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93
  • Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156(6):869-75
  • Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001;11(2):105-10
  • Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161(5):818-25
  • Takano A, Suhara T, Ikoma Y, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 2004;7(1):19-26
  • Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacol 2006;31(5):1027-35
  • Mamo D, Kapur S, Keshavan M, et al. D2 Receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacol 2008;33(2):298-304
  • Zamuner S, Gomeni R, Bye A. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. Nucl Med Biol 2002;29(1):115-23
  • Zamuner S, Gomeni R. Optimal design to estimate the time varying receptor occupancy relationship in a PET experiment. Abstracts of the XVI Annual Meeting of the Population Approach Group in Europe [abstract 1099]. Copenhagen, Danemark, 13-15 June, 2007. 16 [www.page-meeting.org/?abstract = 1099]
  • Lim KS, Kwon JS, Jang I-J, et al. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther 2007;81(2):252-8
  • Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]-IBZM SPECT and [11C]-Raclopride PET. Neuroimage. Corrected Proof, Available online 20 February 2009; accessed 12 March 2009.
  • Key SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr Bull 1987;13:261-76
  • Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol Rep 1962;10:799-812
  • Guy W, editor. ECDEU Assessment manual for Psychopharmacology. 1976, Rockville, MD, U.S. Department of Health, Education, and Welfare
  • Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24(2):192-208
  • Centorrino F, Baldessarrini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of cronically psychotic patients. J Clin Psychopharmacol 1994;14(2):119-25
  • Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl B):133-6
  • Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl B):117-21
  • Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2004;11(3):279-96
  • Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46(5):359-88
  • Odou P, Levron JC, Luyckx M, et al. Risperidone drug monitoring. A useful clinical tool? Clin Drug Invest 2000;19(4):283-92
  • Mauri MC, Laini V, Boscati L, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001;16(1):57-63
  • Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006;20(1):86-90
  • Rowland M. Bioavailability assessment and pharmacologic response: Impact of first-pass loss when both drug and metabolites are active. J Pharmacokinet Biopharm 1988;16(6):573-93
  • Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacol 1994;114(4):566-72
  • Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenics. J Clin Psychopharmacol 1997;17(6):472-7
  • Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21(1):14-20
  • Fellows L, Ahmad F, Castle DJ, et al. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit 2003;25(6):682-9
  • Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005;20(1):55-60
  • Available from: http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify_biopharmr_P1.pdf [Accessed 11 May 2009]
  • Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007;164(9):1411-7
  • Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]-fallypride PET study. Am J Psychiatry 2008;165(8):988-95
  • Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]-fallypride. Neuropsychopharmacology 2008;33(13):3111-25
  • Kirschbaum KM, Müller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008;9(3):212-8
  • Baroldi P, Wolfgang C, Fisher D. A pharmacokinetic–pharmacodynamic relationship exists for efficacy of iloperidone, a novel investigational antipsychotic agent. 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA, 19-24 May 2007
  • Available from: http://www.fda.gov/cder/foi/nda/2006/ 021999s000_ClinPharmR_Part1.pdf [Accessed 11 May 2009]
  • Available from: http://www.fda.gov/cder/foi/nda/2006/021999s000_ClinPharmR_Part2.pdf [Accessed 11 May 2009]
  • Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63(11):992-7
  • Martin JLR, Pérez V, Sacristán M, et al. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006;21(1):11-20
  • Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008;34(2):286-91
  • Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003;30(1):83-103
  • Gomeni R, Lavergne A, Merlo-pich E. Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J Pharm Sci 2009;36(1):4-10
  • Kimko HC, Reele SSB, Holford NHG, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000;68(5):568-77
  • Gomeni R, Merlo-Pich E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 2007;63(5):595-613
  • Piotrovsky V. Indirect-response model for the analysis of concentration-effect relationships in clinical trials where response variables are scores [abstract 773]. Abstracts of the XIV Annual Meeting of the Population Approach Group in Europe. Pamplona, Spain, 16 – 17 June, 2005. 14[www.page-meeting.org/?abstract = 773]
  • Ortega Azpitarte I, Vermeulen A, Piotrovsky V. Concentration-response analysis of antipsychotic drug effects using an indirect response model [abstract 995]. Abstracts of the XV Annual Meeting of the Population Approach Group in Europe. Brugge/Bruges, Belgium, 14– 16 June, 2006. p. 15 [www.page-meeting.org/?abstract = 995]
  • Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia. Clin Pharmacol Ther. Corrected proof. Available on line 22 Apr 2009. dx.doi.org/10.1038/clpt.2009.44
  • de Greef R, Friberg LE, Chapel S, et al. Modeling and simulation to integrate efficacy and safety data following full development: a case study in schizophrenia and bipolar disorder [abstract 1274]. Abstracts of the XVII Annual Meeting of the Population Approach Group in Europe. Marseille, France, 18– 20 June, 2008. 17 [www.page-meeting.org/?abstract = 1274]
  • Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapiramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 2005;20(3):187-99
  • Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy analysis of the contribution of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(3):368-78
  • Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
  • Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008;22(2 Suppl):46-55
  • Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 1995;274(2):921-7
  • Ma G, Friberg LE, Karlsson MO. Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin. Abstracts of the XVII Annual Meeting of the Population Approach Group in Europe [abstract 1299]. Marseille, France, 18– 20 June, 2008. 17[www.page-meeting.org/?abstract = 1299]
  • Friberg LE, Vermeulen AM, Karlsson MO. A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment. Abstracts of the XV Annual Meeting of the Population Approach Group in Europe [abstract 940]. Brugge/Bruges, Belgium, 14– 16 June, 2006. 15[www.page-meeting.org/?abstract = 1299]
  • Friberg LE, Vermeulen AM, Petersson KJF, Karlsson MO. An agonist–antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 2009;85(4):409-17
  • Gabriellsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concept and applications. 3rd edition. Swedish Pharmaceutical Press, 2000. p. 231-51
  • Bagli M, Suverkrup R, Quadflieg R, et al. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 1999;291(2):547-54
  • de Visser SJ, van der Post J, Pieters MSM, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001;51(2):119-32
  • Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159(1):133-5
  • Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-34
  • Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Res 2003;58:32-45
  • Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005;7(3):E609-24
  • Shin JG, Kang WK, Shon JH, et al. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol 2007;63(2):206-15
  • Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-6
  • Goss SL, Ouellet D. Dose and time-response modeling of the effects of marketed products used in treatment of schizophrenia [abstract PII-09]. 2009 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, Maryland March 18–21, 2009. Clin Pharmacol Ther 2009;85(Suppl 1):S40
  • Ahadieh S, Corrigan B, Riley S, Lalonde R. Model based meta analysis of positive and negative syndrome scale (PANSS) in schizophrenic patients [abstract PII-89]. 2009 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, Maryland March 18–21, 2009. Clin Pharmacol Ther 2009;85(Suppl 1):S64
  • Nordström AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152(10):1444-9
  • Kapur S, Roy P, Daskalakis J, et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158(2):311-4
  • Farde L, Nordström AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44
  • Talvik M, Nordström AL, Nyberg S, et al. No support for regional selectivity in clozapine-treated patients: a PET study with [11C]raclopride and [11C]FLB 457. Am J Psychiatry 2001;158(6):926-30
  • Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152(2):173-8
  • Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res Neuroimaging 1996;67(3):163-71
  • Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berlin) 1997;131(2):148-52
  • Fitzgerald PB, Kapur S, Remington G, et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berlin) 2000;149(1):1-5
  • Reimold M, Solbach C, Noda S, et al. Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berlin) 2007;190(2):241-9
  • Tauscher J, Jones C, Remington G, et al. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7(3):317-21
  • Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berlin) 2008;197(2):229-35
  • Gefvert O, Bergström M, Långström B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berlin) 1998;135(2):119-26
  • Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57(6):553-9
  • Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69(1):81-6
  • Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005;8(1):27-36
  • Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006;163(3):396-401
  • Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry 2008;69(8):1281-6
  • Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009;17(3):255-63
  • Uchida H, Graff-Guerrero A, Mulsant BH, et al. Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. Schizophr Res. In Press, Corrected Proof, Available online 28 January 2009, accessed 17 March 2009. doi:10.1016/j.schres.2008.12.022
  • Nyberg S, Olsson H, Nilsson U, et al. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berlin) 2002;162(1):37-41
  • Baldessarini RJ, Tarazi FI. Pharmacotherapy of Psychosis and Mania. In: Brunton LL, Parker KL, Murri N, Blumenthal DK, editors, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition (online). McGraw-Hill

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.